45,335 Shares in Zoetis Inc. $ZTS Purchased by DMKC Advisory Services LLC

Key Points

• DMKC Advisory Services opened a new position in Zoetis, purchasing 45,335 shares worth approximately $3.17 million. Institutional investors and hedge funds collectively own 92.8% of the stock.
• Zoetis reported quarterly EPS of $1.75, beating estimates of $1.51, and revenue of $2.39 billion, above forecasts; revenue was down 1.3% year over year.
• Analysts’ consensus rating was Hold, with an average price target of $101.25. Zoetis also declared a quarterly dividend of $0.53 per share.

DMKC Advisory Services LLC purchased a new position in Zoetis Inc. (NYSE:ZTS - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 45,335 shares of the company's stock, valued at approximately $3,166,000.

A number of other large investors also recently modified their holdings of the business. 71 West Capital Partners increased its position in shares of Zoetis by 14.8% during the third quarter. 71 West Capital Partners now owns 3,241 shares of the company's stock valued at $226,000 after purchasing an additional 418 shares during the period. Kestra Investment Management LLC lifted its position in Zoetis by 122.3% during the 3rd quarter. Kestra Investment Management LLC now owns 10,230 shares of the company's stock worth $714,000 after buying an additional 5,628 shares in the last quarter. AlphaCore Capital LLC grew its holdings in Zoetis by 70.5% during the 3rd quarter. AlphaCore Capital LLC now owns 5,998 shares of the company's stock worth $419,000 after acquiring an additional 2,481 shares during the last quarter. Fulcrum Asset Management LLP grew its holdings in Zoetis by 1,867.8% during the 3rd quarter. Fulcrum Asset Management LLP now owns 61,276 shares of the company's stock worth $4,308,000 after acquiring an additional 58,162 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in Zoetis by 31.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 24,710 shares of the company's stock valued at $1,707,000 after acquiring an additional 5,949 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ZTS shares. Citigroup dropped their target price on shares of Zoetis from $112.00 to $96.00 and set a "buy" rating for the company in a research note on Tuesday, August 11th. Leerink Partners decreased their price target on shares of Zoetis from $95.00 to $80.00 and set a "market perform" rating on the stock in a research note on Monday, July 13th. The Goldman Sachs Group assumed coverage on shares of Zoetis in a report on Friday, October 16th. They issued a "neutral" rating and a $74.00 price target for the company. UBS Group boosted their price objective on shares of Zoetis from $80.00 to $85.00 and gave the stock a "neutral" rating in a research report on Tuesday, October 27th. Finally, Piper Sandler reduced their price objective on Zoetis from $90.00 to $80.00 and set a "neutral" rating on the stock in a report on Monday, August 10th. Eight investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $101.25.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $82.17 on Tuesday. The stock has a market capitalization of $33.95 billion, a P/E ratio of 13.97, a P/E/G ratio of 1.32 and a beta of 0.67. Zoetis Inc. has a 1-year low of $68.77 and a 1-year high of $132.49. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The business has a 50-day moving average price of $75.77 and a two-hundred day moving average price of $92.39.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported $1.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.51 by $0.24. The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company's revenue was down 1.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.70 EPS. Equities analysts predict that Zoetis Inc. will post 6.25 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 dividend on an annualized basis and a yield of 2.6%. Zoetis's dividend payout ratio (DPR) is presently 36.05%.

Zoetis Company Profile

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish.

The company's offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

Zoetis originated as Pfizer's animal health business and became an independent public company in 2013.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.